Clinical Research Details

Descriptive Information
Impact of antibiotic Resistance on Outcomes of NeutropenIC cancer patients with Pseudomonas aeruginosa bacteremia (IRONIC study)

Souha Kanj Shararah



  • Carlota Gudiol MD, PhD. Infectious Diseases Department, Hospital Universitari de Bellvitge
Jeff Jabbour
Conditions and Keywords
Impact of antibiotic resistance on Outcomes of neutropenic cancer patients with Pseudomonas aeruginosa bacteremia
Pseudomonas aeruginosa bacteremia,antibiotic resistance,neutropenic,cancer
Study Design
Other: Describe in Detailed Description
Observation and epidemiological study
N/A: Not Applicable
N/A: Not Applicable
N/A: Not Applicable
N/A: Not Applicable
Eligibility and IRB

Multi-drug resistant Pseudomonas aeruginosa bacteremia is an important cause of bacteremia in neutropenic cancer patients, with an important impact on patients’ outcomes. Multidrug resistance and consequent inadequate initial empirical antibiotic therapy could be associated with increased mortality. The primary objective of this study is to determine the impact of antibiotic resistance on outcomes of neutropenic cancer patients with PA bacteremia, measured by overall (30-day) case-fatality rate.  

Adult cancer patients with neutropenia who were found to have an associated PA bacteremia episode.

The list of patients with hematologic and solid malignancy admitted to the hospital between January 1st 2006 to August 31st 2017 was compiled. The study coordinator screens the medical records of patients and fills an electronic case report form.

1. Adult patients (≥ 18 years)
2. Patients with hematologic diseases and/or hematopoietic stem cell transplant (HSCT) recipients, or with solid organ tumors. 
3. Neutropenia (<500 neutrophils/mm3)
4. Monomicrobial episodes of PA bacteremia 
5. Polymicrobial episodes of bacteremia, in which PA is one of the etiological agents

No exclusion criteria. Patients who do not meet the inclusion criteria above will not be recruited.